Literature DB >> 16829767

Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer.

Walter Jentzen1, Elke Schneider, Lutz Freudenberg, Ernst G Eising, Rainer Görges, Stefan P Müller, Wofgang Brandau, Andreas Bockisch.   

Abstract

AIM: To estimate the individual absorbed dose to the parotid and submandibular salivary glands in radioiodine therapy and its dependence from the previous cumulative therapy.
METHODS: Fifty-five patients with differentiated thyroid carcinoma after thyroidectomy received 1-21 GBq (131)I using single activities of 1-6 GBq. The patients were stratified according to the cumulative activities into low-activity (1-2 GBq), middle-activity (3-7 GBq), and high-activity groups (9-21 GBq). The time-activity curves over the respective salivary glands were derived from multiple static calibrated images measured for each patient up to 48 h after ingestion of the radioiodine therapy capsule with a gamma camera. Manually drawn regions of interests were used to determine the background activities and the activities arising from the salivary glands. The gland volumes were determined by ultrasonography using appropriate volume models.
RESULTS: The median absorbed dose per administered activity of each single parotid and submandibular gland was about 0.15 Gy.GBq (range, 0.1-0.3 Gy.GBq(-1)) and 0.48 Gy.GBq(-1) (range, 0.2-1.2 Gy.GBq(-1)), respectively. The maximum uptake of both gland types was significantly lower for the high-activity than for the low-activity groups and correlated with the mean cumulative administered activity of the activity groups.
CONCLUSION: The iodine uptake of salivary glands is significantly reduced, whereas the absorbed dose per administered (131)I activity was not significantly decreased during the course of therapy. Comparing the well-known dose-effect relationships in external radiation therapy, the absorbed dose per administered (131)I activity is too low to induce comparable radiation damage, suggesting an inhomogeneous distribution of (131)I in human salivary glands.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16829767     DOI: 10.1097/00006231-200608000-00009

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  14 in total

Review 1.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

2.  Sialadenitis following low dose I-131 diagnostic thyroid scan with Thyrogen® (recombinant human thyroid stimulating hormone--thyrotropin alfa).

Authors:  Marta E Gonzalez; Thomas Jose Eluvathingal Muttikkal; Patrice K Rehm
Journal:  J Radiol Case Rep       Date:  2015-06-30

3.  Assessment of salivary gland dysfunction after radioiodine therapy for thyroid carcinoma using non-contrast-enhanced CT: the significance of changes in volume and attenuation of the glands.

Authors:  B Nabaa; K Takahashi; T Sasaki; A Okizaki; T Aburano
Journal:  AJNR Am J Neuroradiol       Date:  2012-05-03       Impact factor: 3.825

4.  Effect of parotid gland massage on parotid gland Tc-99m pertechnetate uptake.

Authors:  Hae Won Kim; Byeong-Cheol Ahn; Sang-Woo Lee; Jaetae Lee
Journal:  Thyroid       Date:  2012-04-23       Impact factor: 6.568

5.  Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET.

Authors:  R F Hobbs; W Jentzen; A Bockisch; G Sgouros
Journal:  Q J Nucl Med Mol Imaging       Date:  2013-03       Impact factor: 2.346

6.  Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems.

Authors:  Walter Jentzen; Reiner Weise; Jürgen Kupferschläger; Lutz Freudenberg; Wolfgang Brandau; Ronald Bares; Wolfgang Burchert; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-10       Impact factor: 9.236

7.  Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.

Authors:  Walter Jentzen; Robert F Hobbs; Alexander Stahl; Jochen Knust; George Sgouros; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

8.  Short-Term Side Effects after Radioiodine Treatment in Patients with Differentiated Thyroid Cancer.

Authors:  Liyan Lu; Fengling Shan; Wenbin Li; Hankui Lu
Journal:  Biomed Res Int       Date:  2016-02-17       Impact factor: 3.411

9.  Effects of first radioiodine ablation on functions of salivary glands in patients with differentiated thyroid cancer.

Authors:  Arun Upadhyaya; Zhaowei Meng; Peng Wang; Guizhi Zhang; Qiang Jia; Jian Tan; Xue Li; Tianpeng Hu; Na Liu; Pingping Zhou; Sen Wang; Xiaoxia Liu; Huiying Wang; Chunmei Zhang; Fengxiao Zhao; Ziyu Yan
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

10.  Estimation of Organ Absorbed Doses in Patients from (99m)Tc-diphosphonate Using the Data of MIRDose Software.

Authors:  Daryoush Shahbazi-Gahrouei; Mohsen Cheki; Masoud Moslehi
Journal:  J Med Signals Sens       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.